Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2022

Conditions
Locally Advanced Rectal Cancer
Interventions
COMBINATION_PRODUCT

Trifluridine/tipiracil chemoradiation

Trifluridine/tipiracil based chemoradiation

COMBINATION_PRODUCT

Capecitabine based chemoradiation

Capecitabine based chemoradiation

Trial Locations (8)

20249

Hämatologisch- Onkologische Praxis Eppendorf (HOPE), Hamburg

20251

II. Medizinische Klinik und Poliklinik Hubertus Wald Tumorzentrum - UCCH, Hamburg

20259

Überörtliche Gemeinschaftspraxis für Innere Medizin Schwerpunkt Hämatologie, Onkologie und Palliativmedizin Dres. Verpoort, Wierecky & Zeller, Hamburg

21680

Klinik Dr. Hancken / MVZ Onkologie, Stade

22767

Hämatologisch- Onkologische Praxis Altona (HOPA), Hamburg

23562

Lübecker Onkologische Schwerpunktpraxis Dres. med. Uthgenannt, Kirso, Weber, Lübeck

24939

Malteser Krankenhaus St. Franziskus Hospital, Flensburg

Unknown

University Medical Center Halle, Halle

All Listed Sponsors
collaborator

Clinical Trial Center North (CTC North GmbH & Co. KG)

OTHER

collaborator

Servier Affaires Médicales

INDUSTRY

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT04177602 - Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial | Biotech Hunter | Biotech Hunter